Preventing coronary heart disease: high baseline risk strategy and cost effectiveness of guidelines

BMJ. 2006 Apr 1;332(7544):793. doi: 10.1136/bmj.332.7544.793.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adult
  • Aged
  • Coronary Disease / prevention & control*
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Practice Guidelines as Topic
  • Risk Assessment
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors